bpc 157 fda compounding category EVEXIAS Life Sciences filing lawsuit over peptides BPC-157 is shifting off FDA

Description

The restored function immediately upon administration might regain reversal of the venous and intracranial hypertension [38] since recovered heart function [38] might ascertain the ability to drain venous blood adequately for a given cerebral blood inflow without raising venous pressures

It is a primary effector molecule of cytotoxic T- and NK-cells [73, 74]

More rigorous clinical studies are needed to determine its safety and efficacy

Daraus kann man nicht einfach eine klare Kausalitt ableiten, aber es reicht definitiv, um nicht so zu tun, als wrden wir hier ber ein harmloses Wellness-Tool sprechen